Key points from article :
Nanovery, developing nanorobots that will be used to diagnose deadly diseases at an early stage, has completed a successful trial with NHS scientists.
Nanovery’s system can detect biomarkers directly in blood serum samples with a simple workflow.
A process typically requires multiple steps and takes many hours or even days.
The trial looked to test the accuracy of the Nanovery technology by comparison to established methods.
The findings demonstrated that the Nanovery process achieved the same level of accuracy but additionally delivered results in a more cost-efficient and timely manner.
Founder of Nanovery, Jurek Kozyra, added, “The work we have done with the ... next stage of validation and commercialisation.”
The company said it has raised over £1.85 million of funding.
